
Alphatec Hlds (ATEC) Stock Forecast & Price Target
Alphatec Hlds (ATEC) Analyst Ratings
Bulls say
Alphatec Holdings Inc. is projected to achieve total revenues of $890 million in 2026, reflecting an anticipated 17% increase from preliminary 2025 revenues, signifying strong growth potential in the medical technology sector. The company has demonstrated impressive surgical metrics, including a sequential acceleration in new surgeon adoption growth of 26% and established territory revenue growth of 30%, which contributed to a year-over-year revenue growth of 25% driven by increased surgical procedure volumes. Additionally, Alphatec's adjusted EBITDA for the latest quarter came in at $26 million, outperforming previous estimates and indicating solid financial performance along with improving margins and free cash flow durability.
Bears say
Alphatec Holdings Inc. is experiencing a negative outlook primarily due to anticipated lower revenue growth and free cash flow (FCF) projections that are not meeting expectations, as evidenced by a 31% drop through on revenue dollar growth and a bear case scenario that suggests even further decline. Furthermore, a slowdown in surgical growth in the fourth quarter, exacerbated by an easier comparative from the previous period, raises concerns about the company’s ability to maintain momentum in a competitive spine market. Risks such as poor sales execution, the impact of the COVID-19 pandemic on procedure volumes, and potential dilutive equity offerings or acquisitions further contribute to the pessimistic sentiment surrounding the stock.
This aggregate rating is based on analysts' research of Alphatec Hlds and is not a guaranteed prediction by Public.com or investment advice.
Alphatec Hlds (ATEC) Analyst Forecast & Price Prediction
Start investing in Alphatec Hlds (ATEC)
Order type
Buy in
Order amount
Est. shares
0 shares